Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

acute kidney injury

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

New blood test could identify individuals at highest risk of developing heart failure

Measuring NPY alongside BNP could help healthcare professionals improve diagnosis for heart patients

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The rare form of kidney disease is estimated to affect around 25 per million adults worldwide

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

- PMLiVE

UKRI announces £80m investment into new UK research hubs for AI research

The nine hubs will help to evolve AI across applications, including healthcare treatments

- PMLiVE

NICE recommends STADA and Calliditas’ Kinpeygo to treat rare kidney disease IgAN

Affecting approximately 14,000 in England, IgA nephropathy occurs when IgA accumulates in the kidneys, causing inflammation and scarring

- PMLiVE

Study reveals Takotsubo syndrome patients failed by current cardiovascular treatments

Takotsubo syndrome patients were found to be as vulnerable to dying as heart attack patients

- PMLiVE

Testing antibodies in blood samples could help prevent heart attacks

People with serious atherosclerosis are more likely to have a serious heart or circulatory problem

- PMLiVE

Study suggests health and lifestyle factors could be linked to young-onset dementia

There are around 370,000 new cases of young-onset dementia globally every year

- PMLiVE

Study identifies new amyloid-forming protein linked to early-onset dementia

The TAF15 protein is a new potential therapeutic for frontotemporal dementia

- PMLiVE

UK-India research project trialling easy-to-use UTI test to support fight against AMR

AMR has been declared by WHO as one of the top ten threats to global public health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links